News

The American Journal of Managed Care21d
Trastuzumab Deruxtecan Plus Pertuzumab Improves PFS vs Standard Care in HER2+ Breast Cancer
She also highlighted a few trial design considerations. Isaacs noted the differing lengths of treatment between arms, with patients on the investigational arm continuing trastuzumab deruxtecan ...
Morningstar21d
Camizestrant reduced the risk of disease progression or death by 56% in patients with advanced HR-positive breast cancer with an emergent ESR1 tumor mutation in SERENA-6 Phase ...
The novel trial design used ctDNA monitoring at the ... diverse breast cancer tumor environment. With fam-trastuzumab deruxtecan-nxki, a HER2-directed ADC, AstraZeneca and Daiichi Sankyo are ...
The New England Journal of Medicine23d
Trastuzumab Deruxtecan or Ramucirumab plus Paclitaxel in Gastric Cancer
We conducted an international, randomized, phase 3 trial comparing second-line trastuzumab deruxtecan at a dose of 6.4 mg per kilogram of body weight with ramucirumab plus paclitaxel in patients ...
Applied Clinical Trials Online12d
First Patient Dosed in Phase III Trial of Enhertu as First-Line Treatment for Endometrial Cancer
In combination with rilvegostomig or Keytruda, Enhertu will be evaluated versus chemotherapy in the DESTINY-Endometrial01 ...
Yahoo Finance20d
ENHERTU® (fam-trastuzumab deruxtecan-nxki) plus pertuzumab reduced the risk of disease progression or death by 44% vs. THP as 1st-line therapy in patients with HER2-positive ...
June 02, 2025--(BUSINESS WIRE)--Positive results from the DESTINY-Breast09 Phase III trial showed ENHERTU ® (fam-trastuzumab deruxtecan-nxki) plus pertuzumab demonstrated a highly statistically ...
Healio23d
Second-line trastuzumab deruxtecan improves survival for advanced gastric cancers
Second-line trastuzumab deruxtecan-nxki significantly improved outcomes for advanced gastric cancers compared with paclitaxel plus ramucirumab. Confirmation of HER2 status after first-line ...
The Bakersfield Californian21d
ENHERTU® (fam-trastuzumab deruxtecan-nxki) plus pertuzumab reduced the risk of disease progression or death by 44% vs. THP as 1st-line therapy in patients with HER2-positive ...
Positive results from the DESTINY-Breast09 Phase III trial showed ENHERTU ® (fam-trastuzumab deruxtecan-nxki) plus pertuzumab demonstrated a highly statistically significant and clinically ...